

## Supplementary Information:

# Longitudinal imaging of T cell-based immunotherapy with multi-spectral, multi-scale optoacoustic tomography

Melanie A. Kimm<sup>1#</sup>, Stratis Tzoumas<sup>2,3#</sup>, Sarah Glasl<sup>2,3</sup>, Murad Omar<sup>2,3</sup>, Panagiotis Symvoulidis<sup>2,3</sup>, Ivan Olefir<sup>2,3</sup>, Ernst J. Rummeny<sup>1</sup>, Reinhard Meier<sup>1</sup>, Vasilis Ntziachristos<sup>2,3\*</sup>

<sup>1</sup> Department of Diagnostic and Interventional Radiology, School of Medicine & Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

<sup>2</sup> Chair for Biological Imaging, School of Medicine & Klinikum rechts der Isar, Technical University of Munich, Munich, Germany


<sup>3</sup> Institute of Biological and Medical Imaging, Helmholtz Zentrum München, Neuherberg, Germany

# These authors contributed equally to this work.


\* Corresponding author

### Correspondance to:


Vasilis Ntziachristos,  
Chair for Biological Imaging,  
School of Medicine,  
Technical University of Munich,  
Ismaningerstr. 22, 81675 Munich, Germany  
phone ++49-89-4140 7211  
fax ++49-89-41406748  
v.ntziachristos@tum.de




**Figure S1. Histological analysis.** One representative tumour of the therapy (**a-c**) and one of the control group (**d-f**) is shown. H&E staining (**a, b**) highlights necrotic and apoptotic areas within the tumour core of the therapy group (**a**) whereas the one of the control group presents vital parts (**b**). Caspase 3 (**b, e**) and Cytochrome C (**c, f**) immunofluorescence (red) reveals apoptotic events only in the tumour of the therapy group (**b, c**). Nuclei counterstaining with DAPI (blue). Scale bar (**a, b, c**) = 200  $\mu\text{m}$ , scale bar (**d, e, f**) = 500  $\mu\text{m}$ .



**Figure S2. T cell viability and functionality following cell labeling.** (a) Fluorescence microscopy images of DiR (left), VT-750 (middle) and double labeled OT-1 T cells (magenta). Nuclear counterstaining with DAPI (blue). Scale bar 5  $\mu$ m. (b) Flow cytometry analysis of OT-1 T cells labeled with VT-750 in full medium (left image, light grey) or serum-free medium (left image, dark grey). Flow cytometry analysis of unlabeled, single and double labeled cells (right). (c) XTT cytotoxicity assay after cell labeling. (d) IFN- $\gamma$  ELISA with double labeled OT-1 T cells. OVA-expressing EG7 cells were used as positive control and parental EL4 cells as negative control. Cells were co-cultured for 24 hours at responder: stimulator ratio 2:1.



**Figure S3. Sensitivity detection of double labeled OT-1 T cells.** (a) Schematic representation of the phantom used for *in vitro* cell MSOT. (b) Optoacoustic image (excitation wav. 760 nm) of double labeled T cells next to a solution of black India ink at a known absorption coefficient. Scale bar 1 cm (c) Comparison of the optoacoustic signal produced using India ink of  $0.5 \text{ cm}^{-1}$  absorbance (760 nm), and 18,700 DiR labeled, VivoTag 750 labeled or double labeled T cells. The bar heights indicate the mean signal over the area imaged and the standard deviations indicate the variation of the optoacoustic signal in this area. (d-f) Study assessing the sensitivity of MSOT in detecting T cells in subcutaneous locations: (d) Colour picture with epifluorescence overlay (green pseudocolour) of the back of a euthanized CD1 mouse where different concentrations of cells were injected in 50  $\mu\text{l}$  volumes. Detection result using MSOT for 50,000 and 30,000 cells (e) and for 15,000 and 5,000 cells (f). The sensitivity limit is accordingly 15,000 T cells in a volume of 50  $\mu\text{l}$ .



**Figure S4. Episcopic fluorescence imaging.** Detection of double labeled OT-1 T cells in lymph nodes (**a**) and in the bone marrow (**b**). Cryosection images with overlaid epifluorescence signal from OT-1 T cells (green colour-coding).